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Objective: The present study was aimed to develop a novel, simple, rapid accurate and precise, stability-indicating reversed-phase high-performance 
liquid chromatography method for the simultaneous estimation of sofosbuvir, velpatasvir, and voxilaprevir in bulk and tablet dosage forms.
Methods: The chromatographic elution was achieved in isocratic mode using the combination of sofosbuvir, velpatasvir, and voxilaprevir in the ratio 
of acetonitrile and water (65:35%v/v) using a Phenomenex C18 column which has specification (150 × 4.6 mm, 5 µ particle size) and the flow rate of 
1.0 ml/min and wavelength (ultraviolet) detection at 220 nm.
Results: The retention time obtained for sofosbuvir, velpatasvir, and voxilaprevir was 2.213 min, 2.568 min, and 2.917 min, respectively. Sofosbuvir, 
velpatasvir, and voxilaprevir and their combination drug product were exposed to acidic, alkali, thermal, photolytic, and oxidative stress conditions. 
The current method was validated according to the ICH guidelines for accuracy, precision, linearity, specificity, and sensitivity.
Conclusion: The method developed is more sensitive, accurate, precise, and robust then the methods reported earlier. Retention time and run time 
were decreased; hence, the method is economical simple and precise. Forced degradation studies indicated for the suitability of the method for stability 
studies of sofosbuvir, velpatasvir, and voxilaprevir. The proposed method can be used for routine quality control analysis test in pharmaceutical 
industries.
Keywords: Sofosbuvir, Velpatasvir, and voxilaprevir, Reversed-phase high-performance liquid chromatography, Stability indicating, Validation.
INTRODUCTION
Hepatitis C virus (HCV) was found to be a commonly attacking disease 
to human beings and was increased day by day. The literature reveals 
that 72% of the patients were suffered from chronic HCV [1]. In early 
stage, 75–85% of the liver is persisted with the virus. These defects 
have been treated by the use of oral form of these combinational drugs, 
respectively [2].
Sofosbuvir is an antiviral drug in the treatment of chronic HCV 
[3,4]. It is chemically isopropyl(2S)-2-[(2R,3R,4R,5R)-5-(2,4-
dioxopyrimidin-1-yl)-4-Fluoro-hydroxy-4-methyl-tetrahydrofuran-
2-yl]methoxy-phenoxy-phosphoryl]amino]propionate [5,6]. 
Sofosbuvir is a white-to-white crystalline powder with a molecular 
formula of C22H29FN3O9P and molecular weight of 529.4 g/mole. 
Its chemical structure is given in Fig. 1. Velpatasvir is an NS5A 





carbonate [7,8]. It is a white to light yellow solid powder with a 
molecular formula of C49H54N8O8 and a molecular weight of 883.02 g/
mole. Its chemical structure is given in Fig. 2.
Voxilaprevir is also a protease inhibitor and acts as a transporter of 




dioxanonacosa-3(12),4,6, 8,10-pentaene-27-carboxamide [9,10]. 
It is a white to light yellow solid powder with a molecular formula 
C40H52F4N6O9S and a molecular weight of 868.94 g/mole. Its chemical 
structure is given in Fig. 3. The literature survey reveals that a very 
few spectroscopic and liquid chromatographic procedures have 
been reported for the determination of sofosbuvir, velpatasvir, 
and voxilaprevir by ultraviolet (UV) and high-performance liquid 
chromatography (HPLC) [11,12]. Therefore, there is a need to develop 
a rapid, sensitive reversed-phase (RP)-HPLC method for simultaneous 




The reference samples of sofosbuvir, velpatasvir, and voxilaprevir were 
provided as a gift sample from spectrum Pharma Research Solutions, 
Hyderabad. VOSEVI tablets labeled to contain sofosbuvir 400 mg, 
velpatasvir 100 mg, and voxilaprevir 100 mg were purchased from 
the local pharmacy store. HPLC grade acetonitrile was purchased from 
Ramkem, Haryana, India. Orthophosphoric acid was purchased from 
Fischer Scientific, Mumbai, India. HPLC grade water was prepared 
using Millipore Milli-Q water purification system used throughout the 
process.
Instrumentation and chromatographic conditions
The present assay was carried out on a Waters HPLC system model 
2695 equipped with 2996 photodiode array detector, autosample 
injector, and column Phenomenex C18 (150 × 4.6 mm, 5 µm), 
respectively. The output signal was monitored and integrated using 
water Empower 2 software. The isocratic mobile phase consisted of 
acetonitrile and water (65:35%v/v), flowing through the Phenomenex 
C18 (150 × 4.6 mm, 5 µm) column at a constant flow rate of 1.0 ml/
min at ambient temperature. The mobile phase was pumped through 
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Preparation of stock and standard solution
Accurately weighed and transferred 100 mg of sofosbuvir, 25 mg of 
velpatasvir, and 25 mg of voxilaprevir working standards into a 25 ml 
clean dry volumetric flask and 15 ml of diluents was added to these 
flasks and sonicated for 30 min and make up to the final volume 
with diluents and labeled as standard stock solution. From the above 
solution, 1 ml from each stock solution was pipette out and taken into a 
10 ml volumetric flask and made up with diluents.
Preparation of sample and standard solution
Ten tablets were accurately weighed and crushed to powder in a 
motor using pestle and weight equivalent to one tablet was transferred 
to 100 ml volumetric flask, about 50 ml of diluents was added and 
sonicated for 25 min, further the volume mark up with diluents and 
filtered. From above solution, 1.0 ml of filtered sample stock solution 
was transferred into 10 ml volumetric flask and made up with diluents.
Method validation
The developed method for sofosbuvir, velpatasvir, and voxilaprevir was 
validated for parameters such as system suitability, linearity, precision, 
accuracy, robustness, limit of detection (LOD), limit of quantification 
(LOQ), and solution stability as per ICH guidelines.
RESULTS AND DISCUSSION
Optimized chromatographic conditions
After systematic and detailed study of the various parameters involved 
in the method, the following conditions were employed:
Instrument Waters 2695 high‑performance 
liquid chromatography
Mobile phase Acetonitrile and water taken in the 
ratio of 65:35%v/v
Flow rate 1.0 ml/min
Column Phenomenex C18 (150×4.6 mm, 5 µ)
Detector wavelength 220 nm
Column temperature 30°C
Injection volume 5 µl
Run time 6 min
Retention time 2.213 min; 2.568 min; and 2.917 min
Diluents Acetonitrile: Water 65:35%v/v
Fig. 1: Chemical structure of sofosbuvir
Fig. 2: Chemical structure of velpatasvir
Fig. 3: Chemical structure of voxilaprevir
the column at a flow rate of 1.0 ml/min with a sample injection volume 
of 5 µl. Detection of the analytes was carried out at a wavelength of 
220 nm.
Fig. 4: Typical optimized chromatogram of sofosbuvir, velpatasvir, and voxilaprevir
Fig. 5: Typical chromatogram of system suitability solution
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Table 1: System suitability test parameter
S.No. Peak name Retention time Peak area USP plate count USP resolution USP tailing
1. Sofosbuvir 2.213 3,340,127 8009.6 1.3
2. Velpatasvir 2.568 639,849 10,285.5 3.4 1.3
3. Voxilaprevir 2.917 645,351 11,637.0 3.1 1.4
Table 2: Linearity data results
Sofosbuvir Velpatasvir Voxilaprevir
Concentration (µg/ml) Peak area Concentration (µg/ml) Peak area Concentration (µg/ml) Peak area
100 406,350 25 75,773 25 83,481
200 814,431 50 160,339 50 160,535
300 1,220,190 75 235,035 75 240,410
400 1,645,779 100 314,221 100 325,656
500 2,034,377 125 386,712 125 406,542
600 2,438,433 150 457,706 150 482,784
Regression equation
y=4072.4x+1076.3








Square of correlation 
coefficient (R2)=0.9998
Table 3: Limit of detection and limit of quantification results
S.No. Parameter Measured values (µg/ml)
Sofosbuvir Velpatasvir Voxilaprevir
1. Limit of 
detection
0.77 0.17 0.23
2. Limit of 
quantification
2.32 0.53 0.70
Table 4: System precision results
Injection No. Peak area response of drugs
Sofosbuvir Velpatasvir Voxilaprevir
1. 1,647,661 314,647 321,504
2. 1,642,234 319,461 321,969
3. 1,654,419 320,401 320,505
4. 1,639,212 314,874 322,831
5. 1,645,086 316,321 323,427
6. 1,643,523 316,300 327,833
Mean 1,644,895 316,967 3230.2





Six replicates of the working standard solution were prepared and 
injected to carry out system suitability parameters such as retention 
time, peak area, United States Pharmacopeia (USP) plate count, USP 
resolution, and USP tailing. The system suitability parameters are given 
in Table 1 and system suitability chromatograms are given in Fig. 5.
Specificity
It is the ability to unequivocally assess the analyte in the presence of 
components that may be expected to be present. Typically, these might 
be including impurities, degradants, or matrix.
Blank placebo interferences
A study to establish the interferences of blank and placebo was 
conducted. Analysis was performed on solution placebo and 
formulation as per the test method. Chromatograms of blank, placebo, 
and formulation solution showed no peaks at the retention time of 
sofosbuvir, velpatasvir, and voxilaprevir peaks. The chromatograms of 
sofosbuvir, velpatasvir, voxilaprevir of standard, formulation, blank, 
and placebo using the proposed method are shown in Figs. 6-9.
Linearity
Diluting aliquots of 0.25, 0.5, 0.75, 1.0, 1.25, and 1.5 ml of standard 
working solution were pipette out from the standard stock solution 
of concentration 100 µg/ml of sofosbuvir, 25 µg/ml of velpatasvir, and 
25 µg/ml of voxilaprevir and these diluted up to mark with diluents. 
Such that, the final concentrations were in the range of 100–600 µg/ml 
sofosbuvir, 25–150 µg/ml velpatasvir, and 25–150 µg/ml voxilaprevir. 
The calibration standard solution of sofosbuvir, velpatasvir, and 
voxilaprevir was injected using a 5 µl injector and the chromatograms 
were recorded at 220 nm and calibration curve was constructed by 
plotting the peak area versus drug concentration. The linearity data 
are presented in Figs. 10-12 and Table 2, and all parameter results are 
within the limits.
LOD and LOQ
A study to establish the LOD and LOQ for sofosbuvir, velpatasvir, and 
voxilaprevir was conducted. Series of very dilute LOD and LOQ solutions 
were prepared as per the test method and injected triplicate into the 
HPLC system. The LOD and LOQ were established based on signal-
to-noise ratio. LOD was established by identifying the concentration 
which given s/n ratio 3, whereas LOQ was established by identifying the 
concentration which gives s/n ratio of about 10. The sensitivity results 
are shown in Table 3. Chromatograms of LOD and LOQ values are given 
in Table 3.
Table 5: Method precision results
Injection No. Peak area response of drugs
Sofosbuvir Velpatasvir Voxilaprevir
1. 1,655,141 317,440 321,302
2. 1,648,499 319,234 321,134
3. 1,642,259 315,111 320,983
4. 1,645,985 320,011 322,422
5. 1,640,340 318,746 325,725
6. 1,645,991 313,611 321,137
Mean 1,646,369 317,359 32,117





It is an analytical method and is defined as agreement between the 
replicate measurements of the sample. It is expressed as the percentage 
coefficient of correlation or relative standard deviation (RSD) of the 
replicate measurements.
134
Asian J Pharm Clin Res, Vol 13, Issue 2, 2020, 131-139
 Padmini and Sankar 
Fig. 9: Chromatogram of formulation
Fig. 8: Chromatogram of standard solution
Fig. 7: Chromatogram of placebo
Fig. 6: Chromatogram of blank
System precision (intraday precision/repeatability)
Working standard preparation of 5 µl solution was injected 6 times into 
the HPLC system and chromatograms were obtained. %RSD of the peak 
area was calculated. The results of system precision studies are shown 
in Table 4.
Method precision
Working sample solutions of 5 µl were injected six preparations into 
the HPLC system and chromatograms were obtained. The %RSD of the 
assay result of six preparations was calculated. The results obtained for 
assay are presented in Table 5.
Intermediate precision/interday precision
Working standard preparation of 5 µl was injected 6 times test 
preparations into the HPLC system and chromatograms were obtained. 
%RSD was determined for peak areas. The results of intermediate 
precision study are reported in Table 6.
Accuracy
A known amount of sofosbuvir, velpatasvir, and voxilaprevir at each 
three concentration levels 50%, 100%, and 150% was added to a pre-
analyzed sample solution and injected in triplicate at each level into the 
HPLC system. The mean percentage recovery of sofosbuvir, velpatasvir, 
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Fig. 10: Standard calibration graph of sofosbuvir

























Fig. 11: Standard calibration graph of velpatasvir





















Fig. 12: Standard calibration graph of voxilaprevir
Fig. 13: Chromatogram of acid degradation
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Fig. 14: Chromatogram of base degradation
Fig. 15: Chromatogram of peroxide degradation
Fig. 16: Chromatogram of thermal degradation
Fig. 17: Chromatogram of ultraviolet degradation
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and voxilaprevir at each level was calculated. The results are presented 
in Tables 7-9.
Robustness
Working standard solution prepared as per test method was injected 
into the HPLC system at variable conditions such as flow rate at 
±0.1 ml/min, mobile organic phase composition by ±10%, and column 




To 1 ml of standard stock solution of sofosbuvir, velpatasvir, and 
voxilaprevir, 1 ml of 1 N hydrochloric acid was added and sonicated for 
30 min at 60°C. The resultant solution was diluted to obtain 400 µg/
ml, 100 µg/ml, and 100 µg/ml solutions and 5 µl solution was injected 
into the system and the chromatograms were recorded to assess the 
stability of the sample (Fig. 13).
Base degradation studies
To 1 ml of standard stock solution of sofosbuvir, velpatasvir, and 
voxilaprevir, 1 ml of 1 N sodium hydroxide was added and sonicated for 
30 min at 60°C. The resultant solution was diluted to obtain 400 µg/ml, 
100 µg/ml, and 100 µg/ml solutions and 5 µl solution was injected 
into the system and the chromatograms were recorded to assess the 
stability of sample (Fig. 14).
Oxidation
To 1 ml of standard stock solution of sofosbuvir, velpatasvir, and 
voxilaprevir, 1 ml of 20% hydrogen peroxide was added separately. 
The solutions were kept for 30 min at 60°C. For HPLC study, the 
resultant solution was diluted to obtain 400 µg/ml, 100 µg/ml, and 
100 µg/ml solutions and 5 µl solution was injected into the system 
and the chromatogram was recorded to assess the stability of sample 
(Fig. 15 and Tables 13-15).
Dry heat degradation studies
The standard drug solution was placed in oven at 105°C for 6 h to 
study dry heat degradation. For HPLC study, the resultant solution 
was diluted to obtain 400 µg/ml, 100 µg/ml, and 100 µg/ml 
solutions and 5 µl solutions were injected into the system and the 
chromatograms were recorded to assess the stability of the sample 
(Fig. 16).
Photostability studies
The photochemical stability of the drug was also studied by exposing 
the 400 µg/ml, 100 µg/ml, and 100 µg/ml solutions to UV light by 
keeping the beaker in UV chamber for 3 days or 200 Watt h/m2 in 
photostability chamber. For HPLC study, the resultant solution was 
diluted to obtain 400 µg/ml, 100 µg/ml, and 100 µg/ml solutions and 
5 µl solutions were injected into the system and the chromatograms 
were recorded to assess the stability of sample.
Fig. 18: Chromatogram of water degradation
Table 6: Intermediate precision results
Injection No. Peak area response of drugs
Sofosbuvir Velpatasvir Voxilaprevir
1. 1,599,406 290,435 305,906
2. 1,589,699 286,001 306,112
3. 1,607,788 289,084 303,179
4. 1,603,244 288,304 303,904
5. 1,616,783 293,396 300,619
6. 1,604,584 291,041 298,809
Mean 1,603,584 289,710 303,088

















50% 200 199.903 99.95 100.10%
200 201.101 100.55
200 200.845 100.42
100% 400 400.714 100.18
400 399.891 99.97
400 200.845 100.15
150% 600 600.435 100.07
600 599.777 99.96
600 597.567 99.59













50% 50 49.898 99.80 99.91%
50 49.751 99.50
50 49.877 99.75
100% 100 100.860 100.86
100 100.659 100.66
100 100.650 100.65




Stress testing under neutral conditions was studied by refluxing the 
drug in water for 6 h at a temperature of 60°C. For HPLC study, the 
resultant solution was diluted to 400 µg/ml, 100 µg/ml, and 100 µg/
ml solutions and 5 µl solutions were injected into the system and the 
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chromatograms were recorded to assess the stability of the sample 
(Fig. 17).
Neutral degradation studies
Stress testing under neutral conditions was studied by refluxing the 
drug in water for 6 h at a temperature of 60°C. For HPLC study, the 
resultant solution was diluted to 400 µg/ml, 100 µg/ml, and 100 µg/ml 
solutions and 5 µl solutions were injected into the system and the 
chromatograms were recorded to assess the stability of the sample 
(Fig. 18).
Proposed procedures for marketed pharmaceutical formulation
The commercial tablet (VOSEVI) was analyzed separating by injecting 
5 µl of standard and sample preparation solutions injected 6 times into 













50% 50 50.461 100.92 100.26%
50 50.398 100.80
50 50.473 100.95
100% 100 99.240 99.24
100 99.194 99.19
100 99.332 99.33
150% 150 151.472 100.98
150 150.790 100.53
150 150.580 100.39
Table 10: Robustness studies of sofosbuvir
Parameter Optimized conditions Used condition Peak area Retention time Plate count Tailing factor
Flow rate±0.1 ml/min 1 ml/min 0.9 ml/min 1,653,051 2.36 9952 1.32
1.1 ml/min 1,621,845 2.05 9689 1.37
Column temperature (5°C) 30°C 25°C 1,685,187 2.29 9454 1.27
35°C 1,656,297 2.19 9309 1.26
Mobile phase composition 
(5%v/v)
65:35 70:30 1,657,274 2.23 9725 1.32
60:40 1,585,079 2.18 9187 1.27
Table 11: Robustness studies of velpatasvir
Parameter Optimized conditions Used condition Peak area Retention time Plate count Tailing factor
Flow rate±0.1 ml/min 1 ml/min 0.9 ml/min 303,267 2.74 10,815 1.30
1.1 ml/min 294,415 2.38 10,649 1.25
Column temperature 
(5°C)
30°C 25°C 307,054 2.59 10,952 1.26
35°C 306,720 2.53 11,617 1.27
Mobile phase 
composition (5%v/v)
65:35 70:30 310,173 2.61 11,907 1.27
60:40 295,196 2.50 10,894 1.29
Table 12: Robustness studies for sofosbuvir, velpatasvir, and voxilaprevir
Parameter Optimized conditions Used condition Peak area Retention time Plate count Tailing factor
Flow rate±0.1 ml/min 1 ml/min 0.9 ml/min 317,961 3.12 12,216 1.30
1.1 ml/min 326,991 2.72 12,661 1.27
Column temperature 
(5°C)
30°C 25°C 315,986 3.00 13,356 1.32
35°C 318,434 2.86 12,231 1.28
Mobile phase 
composition (5%v/v)
65:35 70:30 320,049 3.06 14,599 1.25
60:40 305,351 2.79 12,826 1.23
Table 13: Forced degradation studies results of sofosbuvir
S.No Degradation conditions % peak area Purity angle Purity threshold % degradation Peak purity
1. Acid 72.02 0.164 0.292 8.90 Passes
2. Base 69.50 0.262 0.289 7.97 Passes
3. Peroxide 73.70 0.253 0.290 6.11 Passes
4. Thermal 71.92 0.270 0.291 3.84 Passes
5. Ultraviolet 72.28 0.253 0.287 1.56 Passes
6. Water 71.92 0.264 0.288 0.67 Passes
Table 14: Forced degradation results of velpatasvir
S.No Degradation condition % peak area Purity angle Purity threshold % degradation Peak purity
1. Acid 13.31 0.129 0.360 4.39 Passes
2. Base 13.75 0.329 0.350 3.55 Passes
3. Peroxide 14.21 0.264 0.349 3.06 Passes
4. Thermal 13.85 0.341 0.354 2.37 Passes
5. Ultraviolet 13.84 0.233 0.282 1.51 Passes
6. Water 13.86 0.238 0.363 0.55 Passes
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the HPLC system and chromatograms were recorded. The amount of the 
drug present in marketed tablets was calculated by comparing the peak 
area of standard and sample. The % assay of sofosbuvir, velpatasvir, and 
voxilaprevir was found to be 99–100%. The typical chromatograms of 
standard and sample solutions using the proposed method are shown 
in Table 16.
CONCLUSION
A simple, accurate, precise, and robust method was developed for the 
stability-indicating RP-HPLC method for the simultaneous estimation 
of sofosbuvir, velpatasvir, and voxilaprevir in tablet dosage forms. 
Retention time of sofosbuvir, velpatasvir, and voxilaprevir were found 
to be 2.213 min, 2.568 min, and 2.917 min. %RSD of the sofosbuvir, 
velpatasvir, and voxilaprevir was found to be 0.2 µg/ml, 0.9 µg/ml, and 
0.6 µg/ml, respectively. Percentage recovery was obtained as 100.01%, 
99.91%, and 100.26% for sofosbuvir, velpatasvir, and voxilaprevir, 
respectively. System precision values were found to be 0.3 µg/ml, 
0.8 µg/ml, and 0.8 µg/ml, and method precision values were found to 
be 0.3 µg/ml, 0.8 µg/ml, and 0.6 µg/ml. LOD and LOQ values obtained 
from regression equations of sofosbuvir, velpatasvir, and voxilaprevir 
were 0.7 µg/ml, 0.17 µg/ml, 0.23 µg/ml, 2.32 µg/ml, 0.53 µg/ml, and 
0.70 µg/ml. Regression equation of sofosbuvir y=4072.4x+1076.3, 
velpatasvir y=3069.8x+2589.8, and voxilaprevir y=3228x+974.39, 
respectively. Stress degradation studies were found to be within 
limits. Retention times were decreased and run time was decreased. 
Hence, the method development was simple and economical that can 
be adopted in regular quality control analysis test in pharmaceutical 
industries.
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